Carboplatin and vinorelbine in elderly patients with non-small cell lung cancer

Research output: Contribution to journalArticlepeer-review


Many lung cancers are diagnosed in patients over 70 years of age, but there are little published data on chemotherapy in elderly patients. We therefore activated a phase II study in order to assess the tolerance and activity of carboplatin (80 mg/m2) and vinorelbine (25 mg/m2) administered weekly in patients aged ≤70 with advanced non-small cell lung cancer. Twenty-five patients (22 males, 3 females; performance status ECOG, 0-2; median age, 75 years, range 70-85) were included in the study and are assessable for response and side effects. A total of 162 cycles of therapy have been delivered (median/patient, 6 cycles). Seven partial remissions (28%; 95% confidence interval 5-36%), 8 disease stabilizations, and 10 progressions have been observed. Median time to disease progression was 4 months, and median survival was 5 months (range, 2-25+). Grade III/IV toxicity consisted mainly of leukopenia and neutropenia observed respectively in 5 and 7 patients. In conclusion, the schedule demonstrated activity and good tolerability in this subset of patients. Elderly patients with good performance status and adequate organ function can be safely treated with systemic chemotherapy.

Original languageEnglish
Pages (from-to)1035-1038
Number of pages4
JournalOncology Reports
Issue number6
Publication statusPublished - 1996


  • chemotherapy
  • elderly
  • non-small cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Carboplatin and vinorelbine in elderly patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this